These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 27370343)

  • 1. New Horizons in the Development of Novel Needle-Free Immunization Strategies to Increase Vaccination Efficacy.
    Schulze K; Ebensen T; Riese P; Prochnow B; Lehr CM; Guzmán CA
    Curr Top Microbiol Immunol; 2016; 398():207-234. PubMed ID: 27370343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanotechnology solutions for mucosal immunization.
    Chadwick S; Kriegel C; Amiji M
    Adv Drug Deliv Rev; 2010 Mar; 62(4-5):394-407. PubMed ID: 19931581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Innovations in vaccinology: challenge and opportunities for Africa].
    Diop D; Sanicas M
    Pan Afr Med J; 2017; 26():235. PubMed ID: 28690749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia 2003 to 2006.
    Menzies R; Turnour C; Chiu C; McIntyre P
    Commun Dis Intell Q Rep; 2008 Jun; 32 Suppl():S2-67. PubMed ID: 18711998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New vaccine introduction in the East and Southern African sub-region of the WHO African region in the context of GIVS and MDGs.
    Chauke-Moagi BE; Mumba M
    Vaccine; 2012 Sep; 30 Suppl 3():C3-8. PubMed ID: 22939018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biodegradable polymeric microsphere-based vaccines and their applications in infectious diseases.
    Lin CY; Lin SJ; Yang YC; Wang DY; Cheng HF; Yeh MK
    Hum Vaccin Immunother; 2015; 11(3):650-6. PubMed ID: 25839217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humoral immunity of dTap-IPV vaccine (REPEVAX®) administered one month after dT-IPV vaccine (REVAXIS®) in adults with unknown vaccination history.
    Larnaudie S; Guiso N; Baptiste C; Desaint C; Desforges L; Lebon P; Soubeyrand B; Launay O
    Hum Vaccin; 2010 Oct; 6(10):829-34. PubMed ID: 20864810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dry powder vaccines for mucosal administration: critical factors in manufacture and delivery.
    Wang SH; Thompson AL; Hickey AJ; Staats HF
    Curr Top Microbiol Immunol; 2012; 354():121-56. PubMed ID: 21822816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Broder KR; Cortese MM; Iskander JK; Kretsinger K; Slade BA; Brown KH; Mijalski CM; Tiwari T; Weston EJ; Cohn AC; Srivastava PU; Moran JS; Schwartz B; Murphy TV;
    MMWR Recomm Rep; 2006 Mar; 55(RR-3):1-34. PubMed ID: 16557217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spotlight on DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa).
    Dhillon S
    BioDrugs; 2010 Oct; 24(5):299-302. PubMed ID: 20795752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.
    Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM
    Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    MMWR Recomm Rep; 1997 Mar; 46(RR-7):1-25. PubMed ID: 9091780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel approaches to pediatric vaccine delivery.
    O'Hagan DT; Rappuoli R
    Adv Drug Deliv Rev; 2006 Apr; 58(1):29-51. PubMed ID: 16480788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Public fear of vaccination: separating fact from fiction.
    Amanna I; Slifka MK
    Viral Immunol; 2005; 18(2):307-15. PubMed ID: 16035942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status of active immunization procedures.
    Ferrer-Pí S; Roldán ML
    Paediatrician; 1979; 8(1-2):83-92. PubMed ID: 471518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global routine vaccination coverage, 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Oct; 59(42):1367-71. PubMed ID: 21030941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seroprevalence and vaccination coverage of vaccine-preventable diseases in perinatally HIV-1-infected patients.
    Sticchi L; Bruzzone B; Caligiuri P; Rappazzo E; Lo Casto M; De Hoffer L; Gustinetti G; Viscoli C; Di Biagio A
    Hum Vaccin Immunother; 2015; 11(1):263-9. PubMed ID: 25483544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New routes of administration: epidermal, transcutaneous mucosal ways of vaccination].
    Denis F; Alain S; Ploy MC
    Med Sci (Paris); 2007 Apr; 23(4):379-85. PubMed ID: 17433227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transdermal immunization: biological framework and translational perspectives.
    Mishra DK; Dhote V; Mishra PK
    Expert Opin Drug Deliv; 2013 Feb; 10(2):183-200. PubMed ID: 23256860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hexavalent vaccines for immunization in paediatric age.
    Esposito S; Tagliabue C; Bosis S; Ierardi V; Gambino M; Principi N
    Clin Microbiol Infect; 2014 May; 20 Suppl 5():76-85. PubMed ID: 24460910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.